EORA-213
Alcohol-Use Disorder
Phase IActive
Key Facts
About Eolas Therapeutics
Eolas Therapeutics is a private, clinical-stage biotech founded in 2018, headquartered in Dublin, United States. The company is advancing a pipeline of three drug candidates targeting substance use disorders, with its lead asset, AZD-4041 for Opioid Use Disorder, in Phase II. Eolas's strategy is built on a neuroscience platform focused on modulating neural reward pathways and is supported by non-dilutive funding from grants and strategic partnerships, such as its agreement with AstraZeneca.
View full company profile